[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"systemic-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:systemic-therapy":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,74,97,127,155,180],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100575144","cytoreductive-gastrectomy-after-systemic-therapy-versus-systemic-therapy-alone-for-limited-metastasis-gastric-cancer-100575144",false,"NCT06768463","Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer","Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer: An Open-label Randomized Controll Trial","CYGAS-GC","Inclusion criteria General criteria\n\n* Age 18-75\n* GCLM detected on surgical exploration and demonstrated by histology or cytology\n* Localized peritoneal carcinomatosis (P1 or P2 score), according to the classification of the Japanese Research Society for Gastric Cancer\n* Liver metastasis lesions of maximum diameter ≤5 cm\n* Para-aortic lymph node metastasis below the coeliac axis or above the inferior mesenteric artery (lymph node 16a1\u002Fb2 of maximum diameter≥1cm)\n* Bilateral or unilateral Krukenberg tumors were allowed and considered 1 incurable organ site\n* The accepted patient has two metastases\n* Baseline Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C 1\n* Basic laboratory tests demonstrating adequate bone marrow function (neutrophil count \\> 1500mm3, haemoglobin \\> 8g\u002FdL, platelet count \\> 100,000\u002Fmm3), adequate liver function (bilirubin, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) within upper limits of normal), adequate renal function (serum creatinine within the upper limit of normal)\n* Expected survival \\> 3 months\n* Able to tolerate enteral nutrition and adequate mental capacity to give informed consent\n* Completed 4 cycles of first-line standard-of systemic therapy\n* Repeat diagnostic laparoscopy after first-line treatment prior to randomization demonstrating feasible resection.\n\nEligibility criteria for resection \\& extent of proposed resection\n\n* Staging scans (cross-sectional imaging) demonstrating no extra metastases (lung, bone,...)\n* Cross-sectional imaging demonstrating no local progression of PM\n* PCI score \\\u003C12\n* Cytology +ve alone (no gross PM) permissible for enrolment\n* Feasible R0 resection (reasonable chance of negative margins on histology)\n* Feasible D1, D1+ or D2 lymphadenectomy\n\nExclusion criteria\n\n* Any extra-abdominal metastasis at diagnosis or during systemic treatment.\n* Past history of malignancy other than gastric cancer diagnosed in the last 5 years except for basal cell carcinoma of skin or preinvasive cancer of cervix\n* Patients in the reproductive age who declined to use an adequate means of contraception\n* Significant disease or conditions which, in the investigator's opinion, would exclude patient from the study\n* Uncontrolled concurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia\n* Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnant and lactating females\n* Prior surgical treatment for GC involving resection\n* Clinical or radiological progression during 1st line systemic treatment\n\n  * Patients with radiological progression of LM (determined by RECIST criteria) to be excluded as disease is likely not responding well to 1st line treatment.\n  * Patients with clinical progression of LM as defined by increasing ascites requiring intervention (ascitic tap\u002Fdrain, hospital admission etc) or causing significant symptoms to the patient (tense distended abdomen, early satiety, shortness of breath etc).\n\n    * Ascites volume as a reflection of disease control is difficult to assess and quantify or a reflection of disease progression. (15)\n* Any patient deemed unresectable or requiring extensive resection beyond procedure approved in the study protocol\n\n  * PCI \\> 12\n  * Extensive bowel \u002F mesentery involvement requiring \\>2 separate \u002F non-contiguous small or large bowel resections in addition to the gastrectomy\n  * Involvement of the head of pancreas or bile duct\n  * PM or nodal disease in the hepatoduodenal ligament\n  * Involvement of major vascular structures\n  * Involvement of esophagus precluding a reasonable chance of R0 resection by transhiatal approach Withdrawal Criteria\n* Patient decides to withdraw from the study, or\n* The investigator concludes that it is in the patient's best interest to discontinue study treatment.","ALL","18 Years","75 Years",{"count":21,"type":22},250,"ESTIMATED","INTERVENTIONAL",[25],"NA","The results of the current studies to determine the optimal strategy for metastatic gastric cancer remain contrversial worldwide.\n\nHypothesis: Cytoreductive Gastrectomy After Systemic Therapy will improve survival time for metastasis gastric cancer compared to Systemic Therapy alone.",[28,29,30,31],"Metastatic Gastric Cancer","Gastric Cancer","Systemic Therapy","Cytoreductive Gastrectomy","RECRUITING","2025-08-20",{"date":35,"type":36},"2025-08-27","ACTUAL",{"date":38,"type":36},"2025-08-01",{"date":40,"type":22},"2027-12-10",{"name":42,"class":43},"University Medical Center Ho Chi Minh City (UMC)","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":44},"100580735","phase-3-continuation-of-first-line-therapy-with-radiotherapy-versus-early-switch-to-second-line-therapy-in-oligoprogressive-hcc-100580735","NCT06841172","Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC","Continuation of First-line Therapy With Radiotherapy for Oligoprogression Versus Early Switch to Second-line Therapy in Oligoprogressive Hepatocellular Carcinoma (CROSS): a Multi-center, Randomized, Controlled, Open-label, Phase Ⅲ Trial","Inclusion Criteria:\n\n* 1\\. Histological or cytological confirmation of primary hepatocellular carcinoma (HCC), or diagnosis based on the Clinical Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 edition) issued by the National Health Commission of the People's Republic of China.\n* 2\\. BCLC stage C at the time of first-line systemic treatment.\n* 3\\. Oligoprogression must be confirmed by imaging or histopathology during first-line systemic therapy (FLST). The number of oligoprogressive lesions is limited to 1-5, involving no more than 1-3 organs or systems. These lesions may represent either new metastatic sites or progression of pre-existing lesions. In addition, they must fit one of the two classifications defined in the ESTRO-EORTC consensus on oligometastases: repeat oligoprogression or induced oligoprogression. Oligoprogression may occur within intrahepatic lesions. In the case of lymph node progression, each lymphatic drainage region is considered a separate lesion. For example, the para-aortic lymph nodes (number 16a and number 16b) are each counted as separate lymph node regions.\n* 4\\. Patients must have experienced oligoprogression while receiving their current FLST and must not have previously received any other FLST that resulted in disease progression. Additionally, the current FLST must have maintained disease stability (SD) for at least three months prior to the occurrence of oligoprogression. Furthermore, the expected survival time must be ≥6 months.\n* 5\\. Oligoprogressive lesions must be eligible for radiotherapy and should have at least one measurable lesion that meets RECIST v1.1 criteria; Bone metastases without soft tissue formation are eligible but are considered non-measurable lesions; Bone metastases with soft tissue formation that meet RECIST v1.1 measurable criteria are considered measurable lesions.\n* 6\\. Liver function must be assessed as Child-Pugh score ≤7 points.\n* 7\\. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1.\n* 8\\. Participants must be able to understand and voluntarily sign a written informed consent prior to the initiation of any study-specific procedures and must agree to comply with the treatment and follow-up requirements of the study.\n* 9\\. Male or female patients between 18 and 75 years of age.\n* 10\\. Availability of tumor and blood samples for biomarker assessment.\n\nExclusion Criteria:\n\n* 1\\. Patients who received FLST as adjuvant treatment after curative surgery for HCC.\n* 2\\. Tumor progression occurring within 3 months after initiation of FLST.\n* 3\\. Patients with combined hepatocellular-cholangiocarcinoma (cHCC-CC)\n* 4\\. History of grade ≥3 serious adverse events due to FLST.\n* 5\\. Presence of brain, peritoneal or omental metastases with bleeding after FLST.\n* 6\\. Previous radiation therapy to the site of the oligoprogressive lesion.\n* 7\\. Active untreated hepatitis B, defined as HBsAg positive with HBV DNA levels above the upper limit of normal in the participating center's laboratory.\n* 8\\. Oligoprogressive lesions not amenable to radiotherapy.\n* 9\\. Alpha-fetoprotein (AFP) level ≥10,000 ng\u002FmL at the time of oligoprogression.\n* 10\\. Diagnosis of malignancy other than liver cancer within 3 years prior to enrollment (excluding curatively treated basal cell carcinoma, squamous cell carcinoma of the skin, and\u002For carcinoma in situ).\n* 11\\. Currently participating in any interventional clinical research treatment or having received any other investigational drug or investigational device therapy within the last 4 weeks prior to enrollment.\n* 12\\. Presence of autoimmune disease or other conditions requiring long-term steroid use.\n* 13\\. Severe impairment of the heart, lungs, kidneys, or other vital organs, active infections (other than viral hepatitis), or other serious comorbidities that render the patient unable to tolerate treatment.\n* 14\\. known or suspected allergy to any study drug or to any drug related to this study.\n* 15\\. History of organ transplantation\n* 16\\. Pregnant or breastfeeding women\n* 17\\. Any other factor that the investigator believes may affect the enrollment of patients or the evaluation of study results.",{"count":53,"type":22},132,[55],"PHASE3","This multicenter, prospective, randomized, controlled, open-label, two-arm Phase III clinical trial is designed to evaluate whether adding radiotherapy to oligoprogressive lesions while continuing first-line systemic therapy at the time of oligoprogression can effectively prolong progression-free survival compared to early switching to second-line systemic therapy in oligoprogressive hepatocellular carcinoma.",[58,59,60,30],"OligoProgressive Metastatic Disease","Hepatocellular Carcinoma (HCC)","Radiotherapy",[62,63,64,65],"oligoprogressive","HCC","radiotherapy","first-line systemic therapy","2025-07-31",{"date":38,"type":36},{"date":69,"type":36},"2025-07-21",{"date":71,"type":22},"2028-07-01",{"name":73,"class":43},"Shandong Cancer Hospital and Institute",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":80,"targetDuration":82,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100576673","prospective-collection-of-therapeutic-efficacy-and-safety-data-in-patients-with-unresectable-hepatocellular-carcinoma-100576673","NCT06788353","Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n1, age 18-75 years old; 2. Patients with primary unresectable liver cancer who have not received any previous treatment (in accordance with the AASLD 2018\u002FEASL 2018 Liver Cancer Diagnostic guidelines); Or patients with unresectable liver cancer who recurred for the first time after radical therapy and did not receive any postoperative adjuvant therapy; 3. There is at least one lesion in the liver that can be measured according to mRECIST criteria, and the intrahepatic lesion is a single tumor ≤10.0cm or multiple tumors (the number of tumors ≤10) and the tumor load is less than 50% (three-dimensional reconstruction of CT scan using Vitelacore software \\[version: 6.9.87.1, Canon\\], calculated as proportion of tumor volume to total liver volume) 4. Normal liver tissue volume exceeds 700ml 5, ECOG score 0-1, good general condition 6, liver function Child-Pugh grade A 7. Expected survival time ≥3 months 8. Blood, liver and kidney function meet the following conditions: a) Neutrophil count ≥1.5×109\u002FL b) Platelet count ≥60×109\u002FL c) Hemoglobin concentration ≥90g\u002FL d) Serum albumin concentration ≥30g\u002FL e) bilirubin ≤50umol\u002FL f) AST and ALT were 5 times lower than the upper limit of normal, ALP less than 4 times the upper limit of normal g) prothrombin time less than 6 seconds above the upper limit of normal h) creatinine less than 1.5 times the upper limit of normal\n\nExclusion Criteria:\n\n1. Preoperative imaging examination assessed tumor load \\>50%;\n2. Previous history of hepatic encephalopathy, refractory ascites, or esophageal and gastric varices rupture bleeding;\n3. There are contraindications for TACE treatment, such as portal shunt, isolated hepatic blood flow, and obvious atherosclerosis;\n4. Patients with extrahepatic metastasis;\n5. Allergic to intravenous contrast agents;\n6. Pregnant or lactating women or subjects who plan to have a family within two years; 7, accompanied by HIV, syphilis infection;\n\n8\\. Accompanied by other malignant tumors or had other malignant tumors within 5 years prior to enrollment; 9. Allogeneic organ transplants; 10, serious heart, kidney and other organ dysfunction; 11. Active clinical severe infection \\> Grade 2; 12. Suffering from mental illness may affect informed consent; 13, can not take oral medicine; 14. Participated in other drug clinical trials within 12 months before enrollment; 15. Active gastric or duodenal ulcer occurred 3 months before enrollment; 16. Previous history of liver or adjacent tissue radiotherapy",{"count":81,"type":22},500,"24 Months","OBSERVATIONAL","The malignant degree of middle and advanced liver cancer is very high, and the survival prognosis of patients is very poor. TACE is currently the standard treatment for unresectable liver cancer recommended by several international authoritative guidelines. However, TACE can only extend survival from 8 months to 13 months, and the prognosis for patients with unresectable liver cancer is still not optimistic. In recent years, some studies have suggested that the combination of TACE and systemic therapy can prolong OS and PFS, but a number of prospective studies have found that the combination of TACE and targeted therapy can not improve the prognosis of unresectable liver cancer. However, TACE as a non-radical treatment is difficult to achieve complete tumor necrosis, so it is still unknown which treatment combination can best improve the prognosis. This trial is an observational clinical trial to explore the efficacy and safety of TACE combined targeting\u002Fimmunotherapy for unresectable hepatocellular carcinoma. Clinical data of patients with unresectable liver cancer treated in our hospital from March 2023 to March 2025 are intended to be collected to evaluate the efficacy and safety of TACE combined with different systems for unresectable liver cancer.",[86,30,87],"Transarterial Chemoembolization","Unresectable Hepatocellular Carcinoma","2025-01-19",{"date":90,"type":36},"2025-01-23",{"date":92,"type":36},"2023-03-01",{"date":94,"type":22},"2027-03-01",{"name":96,"class":43},"Sun Yat-sen University",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":44},"100563889","tips-combined-with-lenvatinib-and-pd-1-inhibitor-for-advanced-hcc-with-main-trunk-pvtt-100563889","NCT06622031","TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT","Transjugular Intrahepatic Portosystemic Shunt Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma With Main Trunk Portal Vein Tumor Thrombus: a Multicenter Phase II Study","Inclusion Criteria:\n\n1. diagnosis of primary HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases;\n2. presence of PVTT with III-IV grade by Cheng's criteria;\n3. having PVTT induced portal hypertension;\n4. with or without PVTT induced acute variceal bleeding;\n5. metastases with limited five sites and no more two organs involved;\n6. Number of Intrahepatic tumors were no more than five;\n7. receipt of Lenvatinib and PD-1 inhibitor as the first-line systemic therapy;\n8. classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2;\n9. no history of other malignancies;\n10. agreed to participated in this clinical trial;\n11. Hemameba ≥3.0 x109\u002FL, neutrophil ≥1.5x109\u002FL, hemoglobin≥10.0 g\u002FL, platelet≥100x 109\u002FL, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml\u002Fmin.\n\nExclusion Criteria:\n\n1. recurrent HCC;\n2. PVTT at I-II grade by Cheng's criteria;\n3. age \\\u003C 18 years or \\> 75 years;\n4. advanced HCC with more than five metastases;\n5. Number of Intrahepatic tumors were more than five;\n6. no response to Lenvatinib;\n7. life expectancy less than 3 months.",{"count":105,"type":22},42,[25],"Hepatocellular carcinoma (HCC) with main trunk portal vein tumor thrombus (PVTT) has poor prognosis. The main lethiferous factor is the upper gastrointestinal hemorrhage by PVTT-related portal hypertension, then the second is the tumor-caused death. It is vital to prevent the portal hypertension by PVTT.",[109,110,30],"Hepatocellular Carcinoma","Portal Vein Tumor Thrombus",[112,113,114,115,116,117,118],"Advanced hepatocellular carcinoma","Lenvatinib","Sintilimab","Camrelizumab","Tislelizumab","Transjugular intrahepatic portosystemic shunt","Main trunk portal vein tumor thrombus","2025-01-09",{"date":121,"type":36},"2025-01-13",{"date":123,"type":36},"2024-10-01",{"date":125,"type":22},"2027-08-30",{"name":96,"class":43},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":137,"conditions":138,"keywords":143,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":44},"100565611","ablation-of-pulmonary-oligometastasis-combined-with-system-for-advanced-hepatocellular-carcinoma-100565611","NCT06644430","Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma","Ablation of Pulmonary Oligometastasis Combined With System Compared System Therapy for Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study","Inclusion Criteria:\n\n1. diagnosis of primary HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases;\n2. presence of pulmonary oligometastasis, the metastases found within three month of HCC diagnosis;\n3. metastases with limited five sites and no more two organs involved, with a maximum diameter of ≤5cm;\n4. receipt of first-line systemic therapy for minimum of 3 months before ablation, with controlled intrahepatic tumors and no progression of metastases. Controlled intrahepatic tumors were defined as those showing a partial or stable response according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST);\n5. undergone locoregional treatments, including transarterial artery chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) were included;\n6. classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n7. no history of other malignancies.\n8. life expectancy more than 3 months;\n9. agreed to participated in this clinical trial;\n10. Hemameba ≥3.0 x109\u002FL, neutrophil ≥1.5x109\u002FL, hemoglobin≥10.0 g\u002FL, platelet≥100x 109\u002FL, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml\u002Fmin.\n\nExclusion Criteria:\n\n1. intermediate HCC;\n2. age \\\u003C 18 years or \\> 75 years;\n3. advanced HCC with more than five metastases;\n4. no response to Lenvatinib;\n5. metastases size \\> 5 cm;\n6. life expectancy less than 3 months.","80 Years",{"count":136,"type":22},470,"Ablation has been an effective therapy in treating intrathoracic metastases. However, for hepatocellular carcinoma with pulmonary oligometastasis, ablation of metastases remains relatively unexplored and still needs clinical evidence.",[139,140,141,142,30],"Advanced Hepatocellular Carcinoma","Lung Cancer","Oligometastasis","Ablation",[112,113,144,115,116,114,145,146],"Sorafeinib","Toripalimab","Apatinib","2024-12-01",{"date":149,"type":36},"2024-12-03",{"date":151,"type":36},"2024-10-04",{"date":153,"type":22},"2025-12-30",{"name":96,"class":43},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":177,"leadSponsor":179,"locationsCount":44},"100562952","the-comparison-of-tace-lenvatinib-with-tace-lenvatinib-ablation-for-intermediate-recurrent-hepatocellular-carcinoma-100562952","NCT06609850","The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma","The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma: a Multicenter Randomized Control Study","Inclusion Criteria:\n\n1. 18-75 years;\n2. RHCC diagnosed by imaging;\n3. intermediate-stage RHCC (two to three lesions which at least one was \\>3 cm in size or more than three tumors);\n4. the tumor number was no more than six, and the maximum tumor diameter was ≤5 cm;\n5. absence of extrahepatic metastasis or macrovascular invasion;\n6. Child-Pugh class A or B;\n7. TACE as initial treatment after tumor recurrence and showed no tumor progression after TACE.\n8. life expectance \\>3 months;\n\nExclusion Criteria:\n\n1. under 18 years or over 75 years of age;\n2. primary intermediate-stage HCC;\n3. RHCC with more than six tumors, or single RHCC\n\n(5) RHCC \\>5cm; (6) extrahepatic metastasis; (7) macrovascular tumor thrombus;",{"count":163,"type":22},116,[25],"Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage. However, whether patients could benefit from the ablation for intermediate recurrent HCC (RHCC) is still need high quality clinical evidence. This study is to evaluate the efficacy of ablation combined with TACE and Lenvatinib for the intermediate-stage RHCC.",[167,113,168,142,30],"Recurrent Hepatocellular Carcinoma","Local Therapy",[170,171,172,173,174],"Lenvatinb","Hepatocellular carcinoma","Microwave ablation","Radiofrequency ablation","Cryoablation",{"date":149,"type":36},{"date":123,"type":36},{"date":178,"type":22},"2028-10-30",{"name":96,"class":43},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":187,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":201,"locationsCount":44},"100564662","haic-in-combination-with-pd-1-inhibitors-and-lenvatinib-for-intermediate-and-advanced-hcc-after-the-failure-of-systemic-therapy-recommended-by-bclc-100564662","NCT06632093","HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC","Hepatic Arterial Infusion Chemotherapy in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced Hepatocellular Carcinoma After the Failure of Systemic Therapy Recommended by BCLC","Inclusion Criteria:\n\n1. Has a diagnosis of HCC confirmed by radiology, histology, or cytology;\n2. Barcelona Clinic Liver Cancer (BCLC) stage C with the presence of portal vein tumor thrombus;\n3. Has received previous systemic therapy recommended for HCC by BCLC, and the systemic therapy failed;\n4. Both PD-1inhibitors and Lenvatinib patients received only include marketed drugs but are not limited to HCC approval;\n5. HAIC was performed after the first PD-1 inhibitor\u002F Lenvatinib treatment or before treatment;\n6. Received at least 2 cycles of HAIC；\n7. Has repeated measurable intrahepatic lesions;\n8. Child-Pugh class A or B.\n\nExclusion Criteria:\n\n1. The interval between the failure of systemic therapy and the beginning of combination therapy longer than 3 months;\n2. With other malignant tumors;\n3. Unable to meet criteria of combination timeframe described above.",{"count":188,"type":22},84,"The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with intermediate or advanced-stage hepatocellular carcinoma (HCC) after failure of systemic therapy recommended by BCLC.",[191,192,193,113,194,30],"BCLC Stage B Hepatocellular Carcinoma","BCLC Stage C Hepatocellular Carcinoma","Hepatic Arterial Infusion Chemotherapy","PD-1","2024-10-06",{"date":197,"type":36},"2024-10-08",{"date":199,"type":36},"2024-09-16",{"date":153,"type":22},{"name":202,"class":43},"First Hospital of China Medical University"]